Affimed N.V. (AFMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
AFMD POWR Grades
- Value is the dimension where AFMD ranks best; there it ranks ahead of 84% of US stocks.
- The strongest trend for AFMD is in Value, which has been heading up over the past 179 days.
- AFMD ranks lowest in Momentum; there it ranks in the 4th percentile.
AFMD Stock Summary
- Of note is the ratio of AFFIMED NV's sales and general administrative expense to its total operating expenses; merely 10.69% of US stocks have a lower such ratio.
- In terms of volatility of its share price, AFMD is more volatile than 91.67% of stocks we're observing.
- AFFIMED NV's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -105.58%, greater than the shareholder yield of just 5.73% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to AFFIMED NV, a group of peers worth examining would be CARA, SRRK, INVZ, VIR, and XENE.
- AFMD's SEC filings can be seen here. And to visit AFFIMED NV's official web site, go to www.affimed.com.
AFMD Price Target
For more insight on analysts targets of AFMD, see our AFMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.53 | Average Broker Recommendation | 1.2 (Strong Buy) |
AFMD Stock Price Chart Interactive Chart >
AFMD Price/Volume Stats
| Current price | $0.66 | 52-week high | $5.10 |
| Prev. close | $0.70 | 52-week low | $0.55 |
| Day low | $0.55 | Volume | 1,185,800 |
| Day high | $0.69 | Avg. volume | 1,264,553 |
| 50-day MA | $1.00 | Dividend yield | N/A |
| 200-day MA | $1.95 | Market Cap | 81.57M |
Affimed N.V. (AFMD) Company Bio
Affimed NV is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The company was founded in 2000 and is based in Heidelberg, Germany.
Latest AFMD News From Around the Web
Below are the latest news stories about AFFIMED NV that investors may wish to consider to help them evaluate AFMD as an investment opportunity.
Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue EstimatesAffimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Affimed Reports 2022 Financial Results and Operational ProgressAFM13 combination with AB-101 NK cells: On track for IND filing in H1 2023 and initiation of clinical study in 2023AFM13 monotherapy REDIRECT data: Oral presentation at the AACR annual meetingAFM24: Data from the three ongoing studies expected to be presented at scientific conferences in Q2 or Q3 of 2023AFM28: Clinical phase 1 study is open and recruiting; clinical trial applications now approved in four European countries including Belgium, France, Denmark and SpainAnticipated cash runway into |
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “ |
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer ResearchAn oral presentation on the safety and efficacy from the AFM13 phase 2 monotherapy clinical study (“REDIRECT”) in patients with CD30-positive relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL)A poster presentation from the collaboration with Prof. Björn Önfelt at the KTH Royal Institute of Technology and Karolinska Institute in Stockholm with findings from the study investigating the impact of CD16A shedding on the potential to facilitate serial killing of tumor cells by AFM13-armed |
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody DiscoveryPLZEN, Czech Republic, March 09, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has successfully completed the technology development activities specified under the terms of its research grant entitled “Research and development of a unique biotechnology for the isolation of antibodies with a therapeutic effect”. Under the grant, awarded to AbCheck by the Ministry of |
AFMD Price Returns
| 1-mo | -29.89% |
| 3-mo | -43.10% |
| 6-mo | -66.33% |
| 1-year | -84.86% |
| 3-year | -59.01% |
| 5-year | -67.80% |
| YTD | -46.77% |
| 2022 | -77.54% |
| 2021 | -5.15% |
| 2020 | 112.41% |
| 2019 | -11.90% |
| 2018 | 139.23% |
Continue Researching AFMD
Want to see what other sources are saying about Affimed NV's financials and stock price? Try the links below:Affimed NV (AFMD) Stock Price | Nasdaq
Affimed NV (AFMD) Stock Quote, History and News - Yahoo Finance
Affimed NV (AFMD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...